target audience: TECH BUYER Publication date: Sep 2022 - Document type: IDC MarketScape - Doc Document number: # US49649022
IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions 2022 Vendor Assessment
Content
List of Tables
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
The DCT space is a turbulent and an evolving one. The COVID-19 pandemic accelerated the adoption of DCTs, and technology has been the game changer in enabling the implementation of DCTs. However, the industry is still in a pilot mode, working on defining technology mix and implementation strategy, one study at a time. There is a need to build a playbook to drive the enterprisewide implementation of the DCT model, automatically optimizing the technology mix based on the study type. One is seeing the increasing use of AI/ML being embedded in the technology, a sharpened focus on generating insights from real-world data, and a heightened need to increase access to clinical trials.
This IDC Health Insights study is the first of a two-part life science R&D IDC MarketScape series. With a specific focus on technology solutions in the life science R&D DCT space, this document is a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a DCT technology solution provider. This is the first time that an IDC MarketScape assessment of DCT technology solutions in life science R&D has been performed.
Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology, IDC, noted, "As the ecosystem of technology vendors providing DCT solutions continues to grow exponentially, the industry is struggling to find its partner of choice. Hence, both vendors and sponsors are establishing multiple partnerships. This is a market that is ripe for consolidation. As the market matures, the life science industry will continue to seek out those vendors that can leverage technology to implement DCTs at scale, provide an enriched patient experience, generate real-time data-driven insights to optimize outcomes, and derive measurable business value."